Elanco Animal Health: Piper Sandler raises PT to $18 from $12, maintains Neutral rating.

Elanco Animal Health: Piper Sandler raises PT to $18 from $12, maintains Neutral rating.

Elanco Animal Health (ELAN) has received a significant update from Piper Sandler, with the investment research firm raising its price target for ELAN to $18 from $12. The Neutral rating remains unchanged, reflecting a cautious but optimistic outlook on the company's future performance.

The revised target comes amidst a series of analyst forecasts and insider trading activities surrounding ELAN. According to Quiver Quantitative, multiple analysts have issued price targets for ELAN in the last six months, with a median target of $17.5 [1]. Andrea Alfonso from UBS set a target price of $19.0 on August 8, 2025, while Daniel Clark from Leerink Partners set a target of $18.0 on July 17, 2025 [1].

In terms of insider trading, ELAN insiders have made three purchases in the past six months, with no sales recorded. For instance, R David Hoover purchased 25,000 shares for an estimated $272,557 on an unspecified date [1]. Additionally, hedge fund activity has shown significant interest in ELAN, with 177 institutional investors adding shares to their portfolios and 224 decreasing their positions in the most recent quarter [1].

Despite the positive analyst sentiment, ELAN's stock price has been influenced by broader market conditions and sector-specific concerns. Piper Sandler's decision to raise the price target is a reflection of the company's recent financial performance and the potential for future growth, albeit with a degree of uncertainty.

Investors should continue to monitor ELAN's stock performance and any new analyst ratings or insider trading activities for further insights into the company's prospects.

References:
[1] https://www.quiverquant.com/news/New+Analyst+Forecast%3A+%24ELAN+Given+%2419.0+Price+Target